Fundamental studies on combination effect of cisplatin and peplomycin in the subrenal capsule assay.

スポンサーリンク

概要

• 論文の詳細を見る

• Subrenal capsule assay (SRC assay) was initially developed by Bogden et al. and has been reported to be an effective method for predicting the sensitivity of individual tumor patients to anticancer agents. However, there still remains some inherent problems such as influence of the host immune responses, drug doses, and methods of administration.<BR>Meanwhile, combination chemotherapy has mainly been performed recently against human malignant tumors in the oral region. cis-diamminedichloroplatinum (CDDP) and peplomycin (PEP), which are effective agents against squamous cell carcinomas, have clinically exhibited a combined efficacy.<BR>Despite the observances made in basic experiments as well as clinical trials, single agent chemosensitivity is mainly examined in the study of SRC assay, and few studies were reported as for combination chemotherapy.<BR>Experimental studies, therefore, were made to examine the possibility of combination chemotherapy using CDDP and PEP in SRC assays.<BR>In animals pretreated with minute immunosuppressive doses of X-ray irradiation which had been administered 24 hours prior to tumor implantation, when CDDP was administered before PEP treatment, the combination effect was more pronounced than when CDDP was administered after PEP treatment. Marked inhibition of tumor growth was shown especially when CDDP was administered 24 hours before PEP treatment.<BR>As results of the foregoing studies, SRC assay was acceptable as an experimental model for predicting a combination effect of CDDP and PEP, and recognized that it may provide an important information in the choice of combination chemotherapy.

• 社団法人 日本口腔外科学会の論文

著者

• 川原 正照

  広島大学歯学部口腔外科学第1講座

関連論文

• 興味ある臨床所見を示した中心性巨細胞肉芽腫の1例
• Fundamental studies on combination effect of cisplatin and peplomycin in the subrenal capsule assay.

スポンサーリンク